Biospecifics Technologies is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum (CCH). Co. maintains intellectual property with respect to injectable CCH that treats, among other indications, Dupuytren's contracture (DC), Peyronie's disease (PD), frozen shoulder syndrome, and uterine fibroids. Injectable CCH is approved and marketed under the trademark XIAFLEX® for the treatment of both DC and PD. Co. is evaluating CCH as a treatment for uterine fibroids. Under its license agreement with Endo International plc's (Endo), Endo has the right to develop CCH for frozen shoulder and plantar fibromatosis, and other licensed indications. The BSTC average annual return 10 years is shown above.
The Average Annual Return on the BSTC average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BSTC average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BSTC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|